References
- Murphy F, Sirohi B, Cunningham D. Stem cell transplantation in Hodgkin lymphoma. Expert Rev Anticancer Ther 2007;7: 297–306.
- Deeg J, Socié G. Malignancies after hematopoietic stem cell transplantation: Many questions, some answers. Blood 1998; 91:1833–1844.
- Dores GM, Metayer C, Curtis RE, Lynch C, Clarke A, Glimelius B, Storm H, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population based evaluation over 25 years. J Chin Oncol 2002;20: 3484–3494.
- Forrest D, Hogge D, Nevi11 T, Nantel S, Barnett M, Shepherd J, et al. High dose therapy and autologous hematopoietic stem cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: A comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem cell transplantation. J Clin Oncol 2005;23: 7994–8002.
- Ades L, Guardiola P, Socié G. Second malignancies after allogeneic hematopoietic stem cell transplantation: New insight and current problems. Blood Rev 2002;16:135–146.
- Forrest DL, Nevi11 TJ, Naiman SC, Le A, Brockington DA, Barnett MJ, et al. Second malignancy following high-dose theraphy and autologous stem cell transplantation: Incidence and risk factor analysis. Bone Marrow Transplant 2003;32: 915–923.
- Walker AR, Rothberg PG, Liesveld JL. A case of JAK2 positive essential trombocitemia 16.5 years after autologous marrow transplantation for AML. Bone Marrow Transplant 2007 Apr 2; [Epub ahead of print].
- Vukelja SJ, Krinshnan J, Ward Fr, Redmond Jill. Synchronous Hodgkin's disease and myelofibrosis terminating with granulo-cytic sarcoma and acute megakaryocytic leukaemia. South Med 1990;83:1317–1320.